Oral GLP-1 pills compared: Wegovy pill, Foundayo, Rybelsus and Ozempic tablets, with FDA status, label rules, trial results, side effects and dated prices.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key takeaways
- Two GLP-1 pills are FDA approved for weight management in adults: the Wegovy pill (December 22, 2025) and Foundayo (April 1, 2026).[5]
- Rybelsus and Ozempic tablets contain semaglutide but are approved only for type 2 diabetes.[3]
- In its 64-week trial, the Wegovy pill produced 13.6% average weight loss vs 2.4% on placebo; it must be taken on an empty stomach with a 30-minute wait.[1]
- Foundayo 17.2 mg produced 11.1% vs 2.1% at 72 weeks in adults without diabetes and can be taken with or without food.[2]
- Self-pay (checked 2026-10-06): Wegovy pill $149-$299 a month; Foundayo $149-$349 at regular prices.[8]
In short: Two daily GLP-1 pills are FDA approved for weight management in adults: the Wegovy pill (oral semaglutide, approved December 22, 2025) and Foundayo (orforglipron, approved April 1, 2026). Two more semaglutide tablets, Rybelsus and Ozempic tablets, are approved only for type 2 diabetes. In their main trials, adults lost on average 13.6% of body weight on the Wegovy pill at 64 weeks and 11.1% on the highest Foundayo dose at 72 weeks, versus about 2% on placebo (labels checked on 2026-10-06).
This guide compares the oral options with their FDA status, explains how pills differ from weekly shots, summarizes the label rules for taking them, the trial results, side effects, warnings and self-pay prices, and lists questions for your clinician. It is information only. InstaTuck does not sell or prescribe medicine; whether any of these pills suits you is a decision for you and a licensed clinician after an evaluation. Please research, ask questions and get checked before starting any treatment.
The oral GLP-1 options and their status
| Pill | Active ingredient | FDA status (badge) | Labeled for (general terms) | How it is taken |
|---|---|---|---|---|
| Wegovy pill | Semaglutide (peptide) | FDA approved for weight management (Dec 22, 2025) | Adults with obesity, or overweight plus a weight-related condition; also heart-risk reduction in adults with heart disease | Once daily, morning, empty stomach, up to 4 oz of water, wait 30 minutes |
| Foundayo | Orforglipron (small molecule) | FDA approved for weight management (Apr 1, 2026) | Adults with obesity, or overweight plus a weight-related condition | Once daily, with or without food |
| Rybelsus | Semaglutide | FDA approved for another indication | Adults with type 2 diabetes: blood sugar control and heart-risk reduction | Once daily, same empty-stomach rules |
| Ozempic tablets | Semaglutide | FDA approved for another indication | Same as Rybelsus (shared label) | Once daily, same empty-stomach rules |
Orforglipron is the generic name of Foundayo; any use of orforglipron outside the Foundayo label, such as for type 2 diabetes, is investigational as of this check. Our status badges guide explains what each badge means. For the shots, see weight-loss injections.
How a GLP-1 pill differs from a GLP-1 shot
- Daily vs weekly. All four pills are taken every day; the weight-management shots (Wegovy, Zepbound) are weekly.
- Food and water rules. Semaglutide tablets must be taken on an empty stomach with a small sip of water, then a 30-minute wait before food, drinks or other oral medicines. Foundayo can be taken with or without food.
- Molecule type. Semaglutide is a peptide; the Wegovy tablet contains an absorption enhancer (salcaprozate sodium, SNAC) listed among its ingredients. Only about 1% to 2% of a semaglutide tablet is absorbed, according to the Wegovy label. Orforglipron is a much smaller chemical molecule (molecular weight 902 g/mol in its label) rather than a peptide.
- No needles, but the same class effects. The side effects and warnings are largely the same digestive ones seen with GLP-1 injections.
- Who can use them. The Wegovy injection is also approved for teens 12 and older with obesity; the Wegovy pill and Foundayo are labeled for adults only.
Our injections vs pills comparison weighs the two routes in more depth, and Wegovy pill vs Foundayo compares the two weight pills directly.
What the trials showed
Wegovy pill. In the 64-week trial in the label (Study 7, also published as OASIS 4), 307 adults with obesity, or overweight with a weight-related condition, took semaglutide 25 mg tablets or placebo after a 12-week step-up, plus diet and activity counseling. Average weight change was -13.6% with the tablet and -2.4% with placebo. 76.3% of people on the tablet lost at least 5% of their weight, 59.8% at least 10%, 47% at least 15% and 27.9% at least 20%.
Foundayo. The label reports two 72-week trials. In Trial 1 (3,127 adults without diabetes, published as ATTAIN-1), average weight change was -7.4% on 5.5 mg, -8.3% on 9 mg and -11.1% on 17.2 mg, versus -2.1% on placebo. In Trial 2 (adults with type 2 diabetes), it was -5.1%, -7.0% and -9.6%, versus -2.5%.
| Item | Pill | Placebo |
|---|---|---|
| Wegovy pill 25 mg (64 weeks) | 13.6% | 2.4% |
| Foundayo 17.2 mg, no diabetes (72 weeks) | 11.1% | 2.1% |
| Foundayo 9 mg, no diabetes (72 weeks) | 8.3% | 2.1% |
| Foundayo 17.2 mg, type 2 diabetes (72 weeks) | 9.6% | 2.5% |
Separate trials with different people and lengths; they cannot be compared head to head. Wegovy label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
Source: Wegovy label (Table 11) and Foundayo label (Table 6), DailyMed (checked on October 6, 2026)
| Item | Wegovy pill 25 mg | Placebo |
|---|---|---|
| Lost 5% or more | 76.3% | 31.3% |
| Lost 10% or more | 59.8% | 14.4% |
| Lost 15% or more | 47% | 5.5% |
| Lost 20% or more | 27.9% | 3.1% |
Source: Wegovy prescribing information, Table 11 (Study 7), DailyMed, revised June 2026 (checked on October 6, 2026)
Rybelsus and Ozempic tablets. These were studied for blood sugar in adults with type 2 diabetes, not for weight. In the 26-week monotherapy trial in their shared label, average weight change was -2.3 kg on 7 mg and -3.7 kg on 14 mg, versus -1.4 kg on placebo. That is why they are not a substitute for a weight-management label.
| Item | Value |
|---|---|
| Placebo | 1.4 kg |
| 7 mg tablet | 2.3 kg |
| 14 mg tablet | 3.7 kg |
Adults with type 2 diabetes; kilograms lost from a starting weight of about 88-89 kg. Weight was not the main goal of the trial.
Source: Rybelsus and Ozempic tablets prescribing information, section 14 (DailyMed, revised January 2026) (checked on October 6, 2026)
How they are taken, in general terms
Each label starts low and steps up every 30 days to limit stomach side effects; only your prescriber sets your dose. The Wegovy pill comes in 1.5, 4, 9 and 25 mg tablets, with 25 mg as the label’s maintenance dose. Foundayo comes in 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg tablets, increased at least 30 days apart based on response and tolerability, up to 17.2 mg; the label says to swallow tablets whole and not take more than one a day. Rybelsus (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg) are not interchangeable milligram for milligram.
The semaglutide tablet routine, as the labels describe it
- First thing in the morningTake the tablet on an empty stomach.
- Water only, a littleSwallow it whole with up to 4 ounces (about half a cup) of plain water; no other drinks.
- Wait 30 minutesNo food, drinks or other pills for at least 30 minutes.
- Then breakfastEat and take other medicines after the wait.
Why so strict? The Wegovy label’s pharmacology section reports that semaglutide absorption was higher after a longer fasting period following the dose, and higher with 50 mL of water than with 240 mL. It also notes that blood levels with the 25 mg tablet are predicted to be comparable to the weekly 2.4 mg injection, but more variable from person to person.
Foundayo has no empty-stomach rule. Its label does flag interactions: with strong CYP3A4 inhibitors (some antifungals and antibiotics, for example) the maximum dose is 9 mg; strong CYP3A4 inducers should be avoided; and simvastatin should not exceed 20 mg a day. Because these pills slow stomach emptying, they may affect how other oral medicines are absorbed.
Missed doses and switching, as the labels describe them
The labels treat missed pills differently. The Wegovy label says that if a tablet is missed, skip it and take the next one the following day. The Foundayo label says to take a missed dose as soon as possible without doubling up the next one, and that if 7 or more doses in a row are missed, the dose is restarted lower and stepped up again to limit stomach side effects. The Wegovy label also describes how adults can switch between the weekly injection and the daily tablet for weight or heart-risk reduction, and the Rybelsus label explains switching between Rybelsus and Ozempic tablets, which are not interchangeable milligram for milligram. Any switch, restart or skipped stretch is a conversation with your prescriber, not a do-it-yourself change.
| Wegovy pill | Foundayo | Rybelsus / Ozempic tablets | |
|---|---|---|---|
| Doses a day | One | One (never more than one tablet) | One |
| Food rule | Empty stomach, morning; up to 4 oz water; wait 30 minutes | With or without food | Empty stomach, morning; up to 4 oz water; wait 30 minutes |
| Missed dose (label) | Skip it; take the next one the following day | Take as soon as possible; do not double; restart lower after 7+ missed in a row | Skip it; take the next one the following day |
| Step-up interval | 30 days | At least 30 days | 30 days |
| Birth control pills | Ask your prescriber | Label: non-oral or barrier method for 30 days after starting and after each increase | Ask your prescriber |
| Ages on the label | Adults | Adults | Adults with type 2 diabetes |
Side effects
Digestive side effects are the most common. In Foundayo’s pooled trials, nausea affected 26-35% of people depending on the dose versus 10% on placebo, and vomiting 13-24% versus 4%. Other effects reported in at least 5% include constipation, diarrhea, indigestion, stomach pain, headache, bloating, fatigue, belching, reflux, gas and hair loss. In Rybelsus’s diabetes trials, nausea affected 20% of people on 14 mg versus 6% on placebo. For the Wegovy pill, the label says the types and frequency of common reactions were similar to the Wegovy injection; it also reports dysesthesia (unusual skin sensations) in 5% of tablet users and no placebo users.
| Item | Foundayo 17.2 mg | Placebo |
|---|---|---|
| Nausea | 35% | 10% |
| Diarrhea | 25% | 11% |
| Constipation | 24% | 9% |
| Vomiting | 24% | 4% |
| Abdominal pain | 14% | 7% |
| Indigestion (dyspepsia) | 13% | 4% |
Source: Foundayo prescribing information, Table 1 (pooled Trials 1 and 2), DailyMed, revised July 2026 (checked on October 6, 2026)
For tips on handling nausea and when to call your prescriber, see our GLP-1 side effects guide; the advice applies to pills too.
Serious risks and boxed warnings
All four pills carry a boxed warning about thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. The Foundayo version notes that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, while tumors were seen with GLP-1 products that are active in rodents; the human relevance has not been determined. Label warnings for the class include acute pancreatitis, severe digestive reactions, kidney injury from fluid loss, low blood sugar with insulin or sulfonylureas, allergic reactions, diabetic eye complications in people with type 2 diabetes, gallbladder disease and pulmonary aspiration during anesthesia or deep sedation. Foundayo is not recommended in people with severe gastroparesis or severe liver impairment.
Pregnancy. The Wegovy and Foundayo labels say the medicine may cause fetal harm and should be stopped when pregnancy is recognized. Talk with your prescriber before starting if you could become pregnant or are breastfeeding.
Cost without insurance (checked on 2026-10-06)
NovoCare Pharmacy lists the Wegovy pill at $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg (one month = 30 tablets). Lilly lists Foundayo’s regular self-pay price at $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 and 9 mg) and $349 (14.5 and 17.2 mg) for 30 days, with temporary prices of $149 for 2.5 mg and $199 for 5.5 mg through December 31, 2026, and $299 for 14.5 and 17.2 mg when refills are on time under its purchase-offer terms. NovoCare lists Ozempic tablets self-pay from $149 a month, varying by dose. With commercial coverage, savings cards can lower copays to as little as $25 a month, with limits; government beneficiaries are excluded.
| Item | Low | High |
|---|---|---|
| Wegovy pill | $149 | $299 |
| Foundayo | $149 | $349 |
Wegovy prices: https://www.novocare.com/pharmacy/wegovy.html. Temporary Foundayo offers lower some strengths through 2026-12-31. Prices change; confirm before you plan.
Source: NovoCare Pharmacy (Wegovy) and Lilly Foundayo coverage and savings page (checked on October 6, 2026)
Medicare. The CMS Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) includes all formulations of Wegovy (injection and tablets) and Foundayo for eligible Part D enrollees using them for weight, with a $50 copay and prior authorization. Rybelsus and Ozempic tablets are covered through regular Part D plans for type 2 diabetes. See GLP-1 insurance coverage and compare scenarios in the GLP-1 cost comparison tool.
Compounded and “oral semaglutide drops”
Some websites sell compounded semaglutide as drops, dissolving tablets or capsules. The FDA warns that compounded and other unapproved GLP-1 products are not reviewed for safety, effectiveness or quality, that some use salt forms of semaglutide that differ from the approved ingredient, and that it knows of fraudulent products with false labels. None of these is the Wegovy pill. InstaTuck never links to such sellers; our compounded GLP-1 guide explains the risks.
Is a pill right for you? Questions to explore
A pill may appeal to people who dislike needles or travel often; a weekly shot may suit people who prefer fewer doses or find the morning routine hard. Your other medicines, birth control, digestive health, budget and insurance all matter. Use our BMI calculator and Find My Options to prepare, and bring the questions below. For the full list of approved weight pills, including non-GLP-1 options such as Qsymia and Contrave, see weight-loss pills and appetite suppressants. Whatever you choose, protecting muscle matters: read muscle loss on GLP-1s.
Related guides
Weight-Loss Pills: prescription, over-the-counter and supplements, by evidenceWeight-loss pills by evidence: FDA-approved prescription pills (Wegovy pill, Foundayo, Qsymia, Contrave, orlistat, phentermine), Alli over…
Appetite Suppressants: prescription options vs supplement claimsAppetite suppressants compared from FDA labels: phentermine, Qsymia, Contrave and GLP-1s, plus supplement claims rated and…
GLP-1 Side Effects: common, serious and how they are managedGLP-1 side effects from the FDA labels: common digestive effects by brand, serious risks, the thyroid…
Compounded Semaglutide and Tirzepatide: what FDA says and the risksCompounded semaglutide and tirzepatide explained: not FDA approved, the dated shortage history, FDA safety reports, counterfeit…Tools for this topic
Latest research
How to Read a Weight-Loss Study Headline in 5 StepsFive questions to ask before believing a weight-loss headline: who was studied, how many, how long,…
What’s Coming in 2027: Weight-Loss Treatments Awaiting FDA DecisionsWeight-loss treatments awaiting FDA decisions in 2027: CagriSema, retatrutide, survodutide, MariTide and more, with filing dates,…
Fake and Counterfeit Weight-Loss Drugs: How to Spot ThemCounterfeit Ozempic has reached U.S. pharmacies three times. The FDA alerts, what online test buys found,…Questions to ask a professional
- Would a daily pill or a weekly shot fit my routine and health history better?
- Do any of my other medicines interact, and how should I time them with the pill?
- Do I need to change my birth control while starting or increasing the dose?
- Is there anything in my history, such as thyroid cancer in my family or pancreatitis, that rules these out?
- What will it cost me with my insurance, and what is the plan if I stop?
Frequently asked questions
Is there an FDA-approved GLP-1 pill for weight loss?
Yes, two as of October 2026: the Wegovy pill (oral semaglutide), approved December 22, 2025, and Foundayo (orforglipron), approved April 1, 2026. Both are for adults with obesity, or overweight with a weight-related condition.
Is Rybelsus approved for weight loss?
No. Rybelsus and Ozempic tablets are approved for adults with type 2 diabetes. In a 26-week diabetes trial, average weight change on Rybelsus 14 mg was -3.7 kg vs -1.4 kg on placebo.
Do GLP-1 pills work as well as the shots?
The pill and shot trials were separate studies, so they cannot be compared directly. The Wegovy pill trial showed 13.6% average loss at 64 weeks and the Wegovy shot trial STEP 1 showed 14.9% at 68 weeks.
Why does the Wegovy pill need an empty stomach?
The label requires taking it in the morning on an empty stomach with up to 4 ounces of water and waiting 30 minutes before food, drinks or other pills, because the label reports that absorption is higher with a longer fast after the dose and with less water.
Can I take Foundayo with food?
Yes. The Foundayo label says it can be taken once daily with or without food. Tablets should be swallowed whole, one a day.
What are the side effects of GLP-1 pills?
Mainly digestive: nausea, vomiting, diarrhea, constipation and indigestion, most often while the dose is increasing. All carry a boxed warning about thyroid C-cell tumors seen with GLP-1 medicines in rodents.
How much does the Wegovy pill cost?
At NovoCare Pharmacy (checked 2026-10-06): $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg. Prices can change.
Does Medicare cover the GLP-1 pills for weight?
Through the temporary Medicare GLP-1 Bridge, eligible Part D enrollees can get Wegovy (including tablets) and Foundayo for weight with a $50 copay and prior authorization, from July 1, 2026 to December 31, 2027.
Are compounded semaglutide drops the same as the Wegovy pill?
No. Compounded products are not FDA approved or reviewed for quality, and some use different salt forms of semaglutide. The FDA has warned about fraudulent and mislabeled products.
References
- WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- FOUNDAYO (orforglipron) tablets: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information. Novo Nordisk, via DailyMed. (accessed October 6, 2026) Drug label
- Drugs@FDA: Wegovy tablets, NDA 218316. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
- Drugs@FDA: Foundayo, NDA 220934. U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
- Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Ozempic online pharmacy: self-pay prices and savings. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Foundayo coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
- Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. (accessed October 7, 2026) Government page
- Wharton S, Lingvay I, Bogdanski P, et al.. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). New England Journal of Medicine, 2025. doi:10.1056/NEJMoa2500969 · PMID 40934115 · NCT05564117 (accessed October 6, 2026) Randomized trial
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2032183 · PMID 33567185 · NCT03548935 (accessed October 7, 2026) Randomized trial
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.